tiprankstipranks
Trending News
More News >
Xilio Therapeutics (XLO)
NASDAQ:XLO
US Market
Advertisement

Xilio Therapeutics (XLO) Stock Statistics & Valuation Metrics

Compare
190 Followers

Total Valuation

Xilio Therapeutics has a market cap or net worth of $35.73M. The enterprise value is -$44.28M.
Market Cap$35.73M
Enterprise Value-$44.28M

Share Statistics

Xilio Therapeutics has 51,782,272 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding51,782,272
Owned by Insiders18.26%
Owned by Institutions1.29%

Financial Efficiency

Xilio Therapeutics’s return on equity (ROE) is -3.31 and return on invested capital (ROIC) is -134.62%.
Return on Equity (ROE)-3.31
Return on Assets (ROA)-0.82
Return on Invested Capital (ROIC)-134.62%
Return on Capital Employed (ROCE)-1.38
Revenue Per Employee99.13K
Profits Per Employee-910.02K
Employee Count64
Asset Turnover0.09
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio
PS Ratio0.00
PB Ratio5.00
Price to Fair Value2.90
Price to FCF1.76
Price to Operating Cash Flow2.54
PEG Ratio-0.04

Income Statement

In the last 12 months, Xilio Therapeutics had revenue of 6.34M and earned -58.24M in profits. Earnings per share was -1.09.
Revenue6.34M
Gross Profit6.34M
Operating Income-60.58M
Pretax Income-58.24M
Net Income-58.24M
EBITDA-58.00M
Earnings Per Share (EPS)-1.09

Cash Flow

In the last 12 months, operating cash flow was 21.10M and capital expenditures -58.00K, giving a free cash flow of 21.04M billion.
Operating Cash Flow21.10M
Free Cash Flow21.04M
Free Cash Flow per Share0.41

Dividends & Yields

Xilio Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta-0.08
52-Week Price Change-28.57%
50-Day Moving Average0.74
200-Day Moving Average0.87
Relative Strength Index (RSI)46.96
Average Volume (3m)371.79K

Important Dates

Xilio Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date
Next Earnings Date
Ex-Dividend Date

Financial Position

Xilio Therapeutics as a current ratio of 2.21, with Debt / Equity ratio of 73.50%
Current Ratio2.21
Quick Ratio2.21
Debt to Market Cap0.16
Net Debt to EBITDA0.83
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Xilio Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Xilio Therapeutics EV to EBITDA ratio is -0.07, with an EV/FCF ratio of -0.21.
EV to Sales0.62
EV to EBITDA-0.07
EV to Free Cash Flow-0.21
EV to Operating Cash Flow-0.22

Balance Sheet

Xilio Therapeutics has $89.07M in cash and marketable securities with $7.86M in debt, giving a net cash position of -$81.21M billion.
Cash & Marketable Securities$89.07M
Total Debt$7.86M
Net Cash-$81.21M
Net Cash Per Share-$1.57
Tangible Book Value Per Share$0.33

Margins

Gross margin is 58.82%, with operating margin of -954.95%, and net profit margin of -918.05%.
Gross Margin58.82%
Operating Margin-954.95%
Pretax Margin-918.05%
Net Profit Margin-918.05%
EBITDA Margin-890.56%
EBIT Margin-940.18%

Analyst Forecast

The average price target for Xilio Therapeutics is $5.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$5.00
Price Target Upside614.29% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast
EPS Growth Forecast53.92%

Scores

Smart Score4
AI Score54
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis